Anaplastic lymphoma kinase

Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

Retrieved on: 
Vendredi, mars 1, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Chemical compounds, Lung cancer, Organic compounds, Protein kinase inhibitors, Tyrosine kinase receptors, Anaplastic lymphoma kinase, Piperidines, Pyridines, Non-small-cell lung carcinoma, Cancer, ALK inhibitor, Entrectinib

The CHMPs opinion will now be reviewed by the European Commission (EC), with a decision expected in the coming months.

Key Points: 
  • The CHMPs opinion will now be reviewed by the European Commission (EC), with a decision expected in the coming months.
  • This CHMP opinion represents a step forward in bringing LORVIQUA to patients in Europe living with advanced ALK-positive non-small cell lung cancer who have limited treatment options.
  • LORVIQUA is a TKI that has been shown to be highly active in preclinical lung cancer models harboring chromosomal rearrangements of ALK.
  • ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.

Global Anaplastic Thyroid Cancer Clinical Trials Review, H2 2018 by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - ResearchAndMarkets.com

Retrieved on: 
Lundi, février 25, 2019
Health, Clinical trials, Oncology, Health, Glands, Human anatomy, Thyroid disease, Anaplastic thyroid cancer, Thyroid cancer, Thyroid, Clinical trial, Anaplastic lymphoma kinase

The "Anaplastic Thyroid Cancer Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anaplastic Thyroid Cancer Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Anaplastic Thyroid Cancer Global Clinical Trials Review, H2, 2018" provides an overview of Anaplastic Thyroid Cancer clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Anaplastic Thyroid Cancer.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Retrieved on: 
Jeudi, janvier 17, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, FDA, Medicine, Cancer, Lung cancer, Atezolizumab, Angiogenesis inhibitors, Tyrosine kinase receptors, Chemotherapy, Cancer treatments, Non-small-cell lung carcinoma, Anaplastic lymphoma kinase, Protein kinase inhibitors, Bevacizumab

The FDA recently approved Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) for the initial treatment of people with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.

Key Points: 
  • The FDA recently approved Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) for the initial treatment of people with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
  • Tecentriq is also approved by the FDA to treat people with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy.
  • Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA approved therapy for NSCLC harboring these aberrations prior to receiving Tecentriq.
  • People in Arm A received Tecentriq during the maintenance treatment phase until loss of clinical benefit was observed.

Tyrosine Kinase Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Retrieved on: 
Jeudi, novembre 29, 2018
Tyrosine kinase receptors, Cell signaling, Cell biology, Cancer, Tyrosine-kinase inhibitor, Tyrosine kinase, Protein kinase inhibitor, ROS1, Chronic myelogenous leukemia, VEGF receptor, Epidermal growth factor receptor, Anaplastic lymphoma kinase

NEW YORK, Nov. 28, 2018 /PRNewswire/ --Tyrosine Kinase Inhibitors Market (Product - BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors, Other Tyrosine Kinase Inhibitors; Application - Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer; Distribution Channel - Hospital Pharmacies, Independent Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Key Points: 
  • NEW YORK, Nov. 28, 2018 /PRNewswire/ --Tyrosine Kinase Inhibitors Market (Product - BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors, Other Tyrosine Kinase Inhibitors; Application - Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer; Distribution Channel - Hospital Pharmacies, Independent Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
    This report on the tyrosine kinase inhibitors market analyzes the current and future scenario of the global market.Increasing expenditure on health care, high prevalence and rise in incidence of cancer, and rise in demand for tyrosine kinase inhibitors for lungs cancer & breast cancer treatment are boosting the usage of tyrosine kinase inhibitors.
  • Health benefits of tyrosine kinase inhibitors and focus of companies on expanding indications of existing and pipeline TKIs are major drivers of the global tyrosine kinase inhibitors market.
  • Based on product, the market has been segmented into BCR-ABL tyrosine kinase inhibitor, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor (VEGFR) tyrosine kinase inhibitors, and other tyrosine kinase inhibitors.The product segment of tyrosine kinase inhibitors market has been analyzed based on available approved products, cost-effectiveness, and preference provided by physicians and patients in treating different cancer diseases.
  • Global tyrosine kinase inhibitors market has been segmented as given below:
    Global Tyrosine Kinase Inhibitors Market, by Product, 2016?2026
    Other Tyrosine Kinase Inhibitors (Janus Kinase Inhibitors, Bruton's Kinase Inhibitor, HGFR TKIs, ALK / ROS1 TKIs, etc.)

Bonnie J. Addario Lung Cancer Foundation and ALK-Positive Patient Group Partner to Encourage Members to Join Lung Cancer Registry

Retrieved on: 
Jeudi, septembre 20, 2018
Lung cancer, Tyrosine kinase receptors, Cancer, Bonnie J. Addario Lung Cancer Foundation, Medicine, Anaplastic lymphoma kinase, Non-small-cell lung carcinoma, Health, Protein kinase inhibitors, ROS1, EML4-ALK positive lung cancer

SAN CARLOS, Calif., Sept. 20, 2018 /PRNewswire/ --The Bonnie J. Addario Lung Cancer Foundation (ALCF) is partnering with ALK Positive , an online community of over 1,200 members worldwide dealing with ALK-positive lung cancer, to encourage Lung Cancer Registry membership.

Key Points: 
  • SAN CARLOS, Calif., Sept. 20, 2018 /PRNewswire/ --The Bonnie J. Addario Lung Cancer Foundation (ALCF) is partnering with ALK Positive , an online community of over 1,200 members worldwide dealing with ALK-positive lung cancer, to encourage Lung Cancer Registry membership.
  • "The cure for cancer lies within the patient," said Bonnie J. Addario, 14-year lung cancer survivor and founder of ALCF.
  • "The work that the ALK Positive lung cancer group is doing to advance research for this oncogene, and all lung cancer patients, is critical to creating a paradigm shift.
  • ALK-positive lung cancer is rare, representing only four to seven percent of non-small cell lung cancer cases.

First-Ever Scientific Research Awards Funded by ALK Positive in Partnership with LUNGevity Foundation

Retrieved on: 
Lundi, juin 4, 2018
Tyrosine kinase receptors, Lung cancer, Protein kinase inhibitors, Anaplastic lymphoma kinase, Medicine, Cancer, Clinical medicine, Chemistry, ALK inhibitor, EML4-ALK positive lung cancer

WASHINGTON, June 4, 2018 /PRNewswire-USNewswire/ --Patient support group ALK Positive and LUNGevity Foundation today announced the three recipients of the new ALK Positive Lung Cancer Transformational Research Award.

Key Points: 
  • WASHINGTON, June 4, 2018 /PRNewswire-USNewswire/ --Patient support group ALK Positive and LUNGevity Foundation today announced the three recipients of the new ALK Positive Lung Cancer Transformational Research Award.
  • The ALK Positive Award represents the first time that LUNGevity Foundation, the premier private funder of lung cancer research in the U.S., and ALK Positive have worked together to change outcomes for people diagnosed with ALK-positive lung cancer.
  • Although the awards are specifically for ALK-positive lung cancer research, they have the potential to benefit lung cancer research in general.
  • For more information about ALK Positive, or to make a donation to help fundthe ALK Positive Lung Cancer Transformational Research Awards, please visit www.alkpositive.org .

Case Report in Journal of Thoracic Oncology Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for Patient Diagnosed with Non-Small Cell Lung Cancer

Retrieved on: 
Mardi, mai 1, 2018
Medicine, Clinical medicine, Cancer, Lung cancer, Tyrosine kinase receptors, Oncology, Biopsy, ROS1, Anaplastic lymphoma kinase, Non-small-cell lung carcinoma, Protein kinase inhibitors, Circulating tumor cell

Biocept's circulating tumor cell (CTC)-based assay confirmed detection of a ROS1 gene translocation in a patient diagnosed with non-small cell lung cancer who had previously received chemotherapy and was progressing.

Key Points: 
  • Biocept's circulating tumor cell (CTC)-based assay confirmed detection of a ROS1 gene translocation in a patient diagnosed with non-small cell lung cancer who had previously received chemotherapy and was progressing.
  • The article, "ROS1 in Liquid Biopsies ," was published in the May 2018 issue of the Journal of Thoracic Oncology.
  • TheROS1gene is structurally similar to ALK, andROS1gene rearrangements are found in 12% of non-small cell lung cancer (NSCLC) cases.
  • Biocept's Target Selector liquid biopsy platform has the ability to identify ALK gene translocations in patients using a simple blood sample.

Published Case Study Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for ALK Rearrangements

Retrieved on: 
Vendredi, avril 27, 2018
Medicine, Clinical medicine, Biopsy, Laboratory techniques, Liquid biopsy, Assay, Anaplastic lymphoma kinase

"In this case study, tissue biopsy proved insufficient for providing this information.

Key Points: 
  • "In this case study, tissue biopsy proved insufficient for providing this information.
  • Biocept's assay, using a blood sample, identified rearrangements of the ALK gene, which enabled the use of targeted therapy and extended this patient's life."
  • "We believe that demonstrating clinical utility in clinical settings is important for enhancing further adoption of our Target Selector assays," said Biocept's President and CEO Michael Nall.
  • Biocept's Target Selector liquid biopsy platform has the ability to identify ALK gene translocations in patients using a simple blood sample.